Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997338193> ?p ?o ?g. }
- W2997338193 endingPage "243" @default.
- W2997338193 startingPage "229" @default.
- W2997338193 abstract "Abstract Bortezomib‐induced peripheral neuropathy (BIPN) is a common toxicity associated with the treatment of multiple myeloma (MM), typically requiring dose reduction, delay, or cessation of treatment protocol. This systematic review aimed to investigate risk factors, trends, and variability associated with the development of BIPN. Searches were undertaken using Medline, PubMed, Cochrane Central Register of Controlled Trials, Embase, Scopus, and Web of Science. Additional studies were identified by investigating authors' bibliographic references cited by original and review articles. Articles that reported on neuropathy in phase III randomised control trials involving bortezomib in any treatment arm for the treatment of MM were included in this review. A total of 43 full text articles met criteria, which examined 23 phase III trials (N = 8218). Overall incidence of neuropathy ranged from 8.4% to 80.5% (median = 37.8%) and severe neuropathy (grade 3‐4) ranged from 1% to 33.2% (median = 8%). Similar reports of neuropathy of any grade and severe neuropathy were observed between the newly diagnosed and relapsed cohort. Bortezomib regimens with reduced dose intensity were associated with reduced neuropathy incidence. Increased cumulative dosing levels, intravenous compared with subcutaneous administration and combination therapy with thalidomide were associated with higher rates of BIPN. This analysis revealed that BIPN is a significant toxicity. More sensitive measures are required to capture the incidence and severity of BIPN. Better understanding of risk factors and reversibility profiles will minimise the number of cancer survivors living with residual treatment side effects." @default.
- W2997338193 created "2020-01-10" @default.
- W2997338193 creator A5011795261 @default.
- W2997338193 creator A5024353703 @default.
- W2997338193 creator A5048164891 @default.
- W2997338193 creator A5059290291 @default.
- W2997338193 creator A5060424866 @default.
- W2997338193 creator A5073248279 @default.
- W2997338193 date "2020-01-27" @default.
- W2997338193 modified "2023-10-07" @default.
- W2997338193 title "Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials" @default.
- W2997338193 cites W1608379611 @default.
- W2997338193 cites W1675440191 @default.
- W2997338193 cites W1724355557 @default.
- W2997338193 cites W1730115657 @default.
- W2997338193 cites W1952760452 @default.
- W2997338193 cites W1955748620 @default.
- W2997338193 cites W1970681172 @default.
- W2997338193 cites W1972519999 @default.
- W2997338193 cites W1975539073 @default.
- W2997338193 cites W1989740966 @default.
- W2997338193 cites W1989803279 @default.
- W2997338193 cites W1993959807 @default.
- W2997338193 cites W1994895013 @default.
- W2997338193 cites W1999177459 @default.
- W2997338193 cites W2000246028 @default.
- W2997338193 cites W2004038328 @default.
- W2997338193 cites W2009259402 @default.
- W2997338193 cites W2010818204 @default.
- W2997338193 cites W2015003025 @default.
- W2997338193 cites W2023661149 @default.
- W2997338193 cites W2025871286 @default.
- W2997338193 cites W2032170666 @default.
- W2997338193 cites W2036139631 @default.
- W2997338193 cites W2039496823 @default.
- W2997338193 cites W2039825457 @default.
- W2997338193 cites W2039923434 @default.
- W2997338193 cites W2039944287 @default.
- W2997338193 cites W2043046274 @default.
- W2997338193 cites W2043887851 @default.
- W2997338193 cites W2044957345 @default.
- W2997338193 cites W2050829096 @default.
- W2997338193 cites W2055338149 @default.
- W2997338193 cites W2068888634 @default.
- W2997338193 cites W2070790769 @default.
- W2997338193 cites W2071434932 @default.
- W2997338193 cites W2074669321 @default.
- W2997338193 cites W2075653620 @default.
- W2997338193 cites W2088765731 @default.
- W2997338193 cites W2095756305 @default.
- W2997338193 cites W2096207943 @default.
- W2997338193 cites W2096367061 @default.
- W2997338193 cites W2096812066 @default.
- W2997338193 cites W2098422029 @default.
- W2997338193 cites W2099210388 @default.
- W2997338193 cites W2103289287 @default.
- W2997338193 cites W2104244233 @default.
- W2997338193 cites W2107154392 @default.
- W2997338193 cites W2108235071 @default.
- W2997338193 cites W2111037078 @default.
- W2997338193 cites W2118820477 @default.
- W2997338193 cites W2120780398 @default.
- W2997338193 cites W2124042268 @default.
- W2997338193 cites W2124560610 @default.
- W2997338193 cites W2127192057 @default.
- W2997338193 cites W2127760782 @default.
- W2997338193 cites W2129534936 @default.
- W2997338193 cites W2136795385 @default.
- W2997338193 cites W2141183397 @default.
- W2997338193 cites W2142368474 @default.
- W2997338193 cites W2150878522 @default.
- W2997338193 cites W2151595053 @default.
- W2997338193 cites W2156098321 @default.
- W2997338193 cites W2156748957 @default.
- W2997338193 cites W2166059514 @default.
- W2997338193 cites W2169183166 @default.
- W2997338193 cites W2169754393 @default.
- W2997338193 cites W2172122039 @default.
- W2997338193 cites W2193716145 @default.
- W2997338193 cites W2302708051 @default.
- W2997338193 cites W2311936801 @default.
- W2997338193 cites W2319764074 @default.
- W2997338193 cites W2343386476 @default.
- W2997338193 cites W2418929756 @default.
- W2997338193 cites W2465965969 @default.
- W2997338193 cites W2482033962 @default.
- W2997338193 cites W2512106959 @default.
- W2997338193 cites W2567188480 @default.
- W2997338193 cites W2573422825 @default.
- W2997338193 cites W2596490933 @default.
- W2997338193 cites W2605819205 @default.
- W2997338193 cites W2608053585 @default.
- W2997338193 cites W2621719068 @default.
- W2997338193 cites W2772566228 @default.
- W2997338193 cites W2794075015 @default.
- W2997338193 cites W2892218501 @default.
- W2997338193 cites W2991792334 @default.
- W2997338193 doi "https://doi.org/10.1002/hon.2706" @default.